On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...